Use the hyperlinks, where available to access additional clinical trial information.
Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma
Other Non-Commercial Sponsor
University of Liverpool
Eligible patients will be randomised to receive 375 mg/m2 of intravenous rituximab alone, 375 mg/m2 of intravenous rituximab in combination with oral lenalidomide or no further treatment, based on their response to a PET-scan (positive or negative).